Colzyx operates in the area of wound management.
Colzyx is based on ground breaking and innovative discoveries from the Medical Faculty at Lund University, Lund, Sweden.
Our scientific work demonstrates that the alpha-3 chain from the human collagen VI molecule exhibits unprecedented wound healing and antimicrobial effects. These are used in Colzyx´ product development of novel and unique forms of bioactive wound dressings.
We utilize naturally occurring, powerful biological regeneration mechanisms to accelerate the wound healing process and to protect the patient against the whole spectrum of common and multidrug-resistant bacteria.
Colzyx is currently developing an innovative wound dressing product that will transform wound care. The solution is unique because it treats acute wounds by combining the body’s natural collagen type VI with a biomembrane. As a result, the healing process takes place in a more effective manner and the product itself is a more skin-friendly solution.
The problem of bacterial resistance to antibiotics is growing and has been highlighted by national and international health organisations. The WHO has created a priority list of bacteria that are of greatest threat to human health. The effectiveness of using collagen IV peptides against these pathogens has been shown by Colzyx in multiple studies, thus proving that WOUNDCOM has the potential to meet societal and global need for new advanced bioactive wound dressings.
The global wound care market is predicted to grow at 6% per year to reach USD 22 billion in a couple of years and includes >250m acute wound cases. WOUNDCOM is applicable to three wound care segments which make up approximately 20% of the global wound care market. The total addressable market for our product is worth around USD 4.5 billion.